Among patients with heart failure (HF), those taking dapaglifozin or empaglifozin had a 30% odds reduction in HF hospitalization, 14% odds reduction in cardiovascular mortality, and a 10% odds ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback